STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism (STRATEGY-PE)
Real-World Comparative Effectiveness and Safety of Anticoagulation, Thrombolysis, and Mechanical Thrombectomy in Intermediate-Risk Acute Pulmonary Embolism: A Multicenter Prospective Cohort Study
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Background: Acute pulmonary embolism (PE) is a severe manifestation of venous thromboembolism (VTE). Intermediate-high risk PE accounts for 20-30% of all PE cases with significant mortality driven by right ventricular (RV) dysfunction. Current guidelines recommend anticoagulation for all, with thrombolysis or mechanical thrombectomy as rescue or alternative therapies. However, there is significant heterogeneity in real-world treatment selection and a lack of head-to-head comparative evidence among the three strategies in complex real-world populations.
Objective: To compare the 30-day and 90-day all-cause mortality and 48-hour RV/LV ratio improvement rate among three treatment strategies (Anticoagulation, Thrombolysis, Mechanical Thrombectomy) in patients with intermediate-high risk acute PE.
Design: This is a prospective, multicenter, non-randomized, pragmatic cohort study. Treatment allocation is based on routine clinical decision-making (natural allocation) without investigator intervention. Advanced statistical methods (Propensity Score Matching/Weighting, Instrumental Variable analysis) will be used to control for confounding factors.
Participants: 1,300 patients with confirmed acute intermediate-high risk PE (RV/LV ratio ≥0.9 and elevated cardiac biomarkers, hemodynamically stable). There are no age limits to reflect real-world diversity.
Interventions/Exposures:
- Anticoagulation (AC): Standard anticoagulant therapy (LMWH, DOAC, UFH, or Warfarin).
- Thrombolysis (TL): Systemic thrombolysis or Catheter-Directed Thrombolysis (CDT) using agents like Urokinase, Alteplase, etc.
- Mechanical Thrombectomy (MT): Mechanical removal of thrombus using FDA/NMPA approved devices (e.g., Indigo, FlowTriever, Acoscream), with or without adjunctive anticoagulation/thrombolysis.
Outcomes:
- Primary: 30-day and 90-day all-cause mortality; 48-hour RV/LV ratio improvement rate (≥15% reduction).
- Secondary: Clinical deterioration, major bleeding (ISTH/GUSTO/BARC), functional status (6MWT, NYHA, PVFS), quality of life (PEmb-QoL, EQ-5D-5L), PE recurrence, and healthcare resource utilization.
Follow-up: Patients will be followed at 48 hours, 7 days, 30 days, and 90 days.
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:he xu Dr, doctor
- 電話番号:+86 153 6611 0045
- メール:kilogram@163.com
研究場所
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210006
- Nanjing First Hospital
-
コンタクト:
- Interventional Vascular Department Director, doctor
- 電話番号:+86-25-52271000
- メール:kilogram@163.com
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Age unlimited (reflecting real-world population).
- Symptom duration of acute PE ≤ 14 days.
- Confirmed acute PE by CTPA involving main or lobar pulmonary arteries.
- Defined as Intermediate-High Risk PE meeting all of the following:
- RV/LV ratio ≥ 0.9 (by CT or Echocardiography).
- Elevated cardiac biomarkers (Troponin > 99th percentile or BNP > 100 pg/mL).
- Hemodynamically stable (SBP ≥ 90 mmHg, no vasopressors required).
- Able to provide informed consent and complete follow-up.
Exclusion Criteria:
- Already received thrombolysis or mechanical thrombectomy for the current episode prior to enrollment.
- Unable to obtain baseline or follow-up CTPA imaging.
- (Note: Unlike strict RCTs, patients with cancer, renal insufficiency, or advanced age are NOT excluded to ensure real-world representativeness).
研究計画
研究はどのように設計されていますか?
デザインの詳細
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
介入・治療介入・治療 |
|---|---|
|
Anticoagulation Cohort
Patients receiving standard anticoagulation therapy alone without thrombolysis or mechanical thrombectomy.
|
Low Molecular Weight Heparin (LMWH), Direct Oral Anticoagulants (DOAC), Unfractionated Heparin (UFH), or Warfarin according to guideline-standard regimens.
他の名前:
|
|
Thrombolysis Cohort
Patients receiving systemic thrombolysis or catheter-directed thrombolysis.
|
Any FDA/NMPA approved mechanical thrombectomy device (e.g., Indigo, FlowTriever, Acoscream) used for clot removal.
他の名前:
|
|
Mechanical Thrombectomy Cohort
Patients undergoing mechanical thrombectomy procedures using percutaneous devices.
|
Urokinase, Pro-urokinase, Alteplase, or Tenecteplase administered systemically or via catheter.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
All-Cause Mortality at 30 Days
時間枠:30 days
|
The percentage of participants who die from any cause within 30 days of enrollment.
|
30 days
|
|
All-Cause Mortality at 90 Days
時間枠:90 days
|
The percentage of participants who die from any cause within 90 days of enrollment.
|
90 days
|
|
Right Ventricular to Left Ventricular (RV/LV) Ratio Improvement Rate at 48 Hours
時間枠:48 hours ± 6 hours
|
The proportion of participants with a reduction in RV/LV ratio ≥15% from baseline measured by CTPA or Echocardiography.
|
48 hours ± 6 hours
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Major Bleeding Events
時間枠:48 hours, 7 days, 30 days, 90 days
|
Incidence of major bleeding defined by ISTH, GUSTO, or BARC criteria (including intracranial hemorrhage).
|
48 hours, 7 days, 30 days, 90 days
|
|
Clinical Deterioration
時間枠:48 hours, 7 days
|
Composite of hemodynamic instability, need for rescue therapy (escalation to thrombolysis/MT/ECMO), intubation, or PE-related death.
|
48 hours, 7 days
|
|
6-Minute Walk Test (6MWT) Distance
時間枠:30 days, 90 days
|
Change in walking distance from baseline (estimated) to follow-up.
Minimal Clinically Important Difference (MCID) ≥30 meters.
|
30 days, 90 days
|
|
Post-VTE Functional Status (PVFS) Score
時間枠:30 days, 90 days
|
Assessment of functional limitation due to VTE (Scale 0-5).
|
30 days, 90 days
|
|
Quality of Life (PEmb-QoL)
時間枠:90 days
|
The questionnaire consists of 9 questions containing 40 items, which are organized into 6 domains: Frequency of Complaints (FC): Assesses the frequency of respiratory and general symptoms (e.g., dyspnea, chest pain). Daily Activity Limitations (AL): Measures limitations in performing activities of daily living (ADL). Work-related Problems (WP): Evaluates difficulties in performing work or school duties. Social Limitations (SL): Assesses restrictions on social activities. Intensity of Complaints (IC): Measures the severity of pain and breathlessness. Emotional Complaints (EC): Captures anxiety, frustration, and fear related to the disease. |
90 days
|
|
Symptomatic PE Recurrence
時間枠:90 days
|
Confirmed recurrent PE via CTPA or V/Q scan.
|
90 days
|
|
ICU Length of Stay
時間枠:From ICU admission to ICU discharge, assessed up to 30 days
|
Duration of intensive care unit stay during the index hospitalization
|
From ICU admission to ICU discharge, assessed up to 30 days
|
|
Total Hospital Length of Stay
時間枠:From hospital admission to hospital discharge, assessed up to 90 days
|
Duration of index hospitalization from emergency department admission to hospital discharge
|
From hospital admission to hospital discharge, assessed up to 90 days
|
|
Total Medical Costs
時間枠:Through 90 days
|
Direct medical costs incurred during index hospitalization and within 90 days of enrollment, including medications, procedures, and hospitalization
|
Through 90 days
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Biomarker Improvement (Troponin, BNP, D-Dimer)
時間枠:48 hours, 7 days
|
Percentage reduction in cardiac biomarkers and D-Dimer levels.
|
48 hours, 7 days
|
|
Daily Step Count
時間枠:Continuous monitoring through 90 days
|
Average daily step count measured by smart band (e.g., Xiaomi/Huawei/Apple Watch) during the 90-day follow-up period.
Assessed as a continuous variable (steps/day) and correlated with 6-Minute Walk Test distance and Post-VTE Functional Status score.
|
Continuous monitoring through 90 days
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 血管疾患
- 心血管疾患
- 気道疾患
- 肺疾患
- 塞栓症と血栓症
- 塞栓症
- 血栓塞栓症
- 肺塞栓症
- 静脈血栓塞栓症
- 薬理作用の分子機構
- フィブリン調節剤
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 硫黄化合物
- 有機化学物質
- ピリジン
- 複素環化化合物、1リング
- 複素環化化合物
- ベンジミダゾール
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- ピラ
- 薬理学的行動
- 化学作用と用途
- 治療用途
- 炭水化物
- ヒドロラーゼ
- 酵素
- 酵素と補酵素
- 血液タンパク質
- ヘパリン、低分子量
- グリコサミノグリカン
- 多糖
- モルホリン
- オキサジン
- チオフェン
- クマリン
- ベンゾピランス
- エンドペプチダーゼ
- ペプチドヒドロラーゼ
- セリンエンドペプチダーゼ
- セリンプロテアーゼ
- プラスミノーゲン活性化因子
- 血液凝固因子
- 心血管剤
- 4-ヒドロキシクマリン
- 組織プラスミノーゲン活性化因子
- 血液因子
- リバロキサバン
- ダビガトラン
- テネクテプラーゼ
- エノキサパリン
- ワルファリン
- ヘパリン
- 抗凝固剤
- 線維溶解剤
- アピキサバン
- エドキサバン
- Urokinase-Type Plasminogen Activator
その他の研究ID番号
その他の研究ID番号
- KY20260205-04
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD 共有時間枠
IPD 共有アクセス基準
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。